Spyre Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-36.2Mn |
Net Profit Margins | -Inf% |
Spyre Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Spyre Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.
Spyre Therapeutics, Inc. Common Stock’s net profit jumped 1.41% since last year same period to $-36.2Mn in the Q2 2026. On a quarterly growth basis, Spyre Therapeutics, Inc. Common Stock has generated 47.54% jump in its net profits since last 3-months.
Spyre Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Spyre Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.71 |
EPS Estimate Current Year | -0.71 |
Spyre Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.71 - a -10.18% fall from last quarter’s estimates.
Spyre Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.71.
Key Ratios
Earning Per Share (EPS) | -0.36 |
Spyre Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 26.53% since last year same period to -0.36 in the Q2 2026. This indicates that the Spyre Therapeutics, Inc. Common Stock has generated 26.53% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-04 | -0.71 | -0.36 | 49.3% |
2026-05-05 | -0.64 | -0.74 | -14.84% |
